Centers for Accelerating Phage (Bacteriophage) Therapy to Combat ESKAPE Pathogens (CAPT-CEP) (P01 Clinical Trial Not Allowed)
ID: 356813Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356813

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-24-069.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens," aimed at establishing research centers dedicated to developing phage therapy as an alternative to traditional antibiotics for multidrug-resistant ESKAPE pathogens. The initiative seeks to support collaborative projects that will create innovative preclinical assays, tools, and models to enhance research and clinical development of phage therapeutics, addressing the critical issue of antibiotic resistance. With an anticipated budget of $6 million, NIH plans to fund 2-3 applications, each with a maximum budget of $1.2 million per year over a potential five-year project period. Interested applicants can find more information and guidelines at the NIH grants website and should submit their applications by January 28, 2025.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-AI-24-069-Full-Announcement.html
    RFA-AI-24-069.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is issuing a funding opportunity titled "Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens." The purpose of this funding initiative is to establish research centers focused on the development of phage therapy as a viable alternative to traditional antibiotics against multidrug-resistant ESKAPE pathogens. The program aims to create innovative preclinical assays, tools, and models to facilitate robust research and clinical development of phage therapeutics. The funding opportunity will support collaborative projects that engage multidisciplinary teams in the research and development of phage therapies targeting specific ESKAPE pathogens. Applicants may submit more than one application, ensuring that each is scientifically distinct. With an anticipated budget of $6 million, NIH expects to fund 2-3 applications, each with a maximum budget of $1.2 million per year over a potential five-year project period. Applications are required to follow strict guidelines and demonstrate significant collaborative efforts, innovative strategies, and effective management plans to advance the understanding and development of phage therapy. This initiative is critical in addressing the pressing issue of antibiotic resistance, reducing the associated health risks, and promoting successful treatment outcomes for bacterial infections.
    Similar Opportunities
    Combating Antibiotic-Resistant Bacteria Interdisciplinary Units (CARBIRUs) (P01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Combating Antibiotic-Resistant Bacteria Interdisciplinary Units" (CARBIRUs) aimed at supporting multidisciplinary research programs to combat antibiotic-resistant bacterial infections. The initiative seeks to assemble cohesive research teams from various disciplines to enhance understanding of bacterial resistance mechanisms and improve strategies for prevention, diagnosis, and treatment. With a total funding amount of $10 million allocated for 4-5 awards, individual budgets may reach up to $1.5 million per year over a maximum project duration of five years. Interested applicants, including higher education institutions and nonprofits, must submit their proposals through Grants.gov by March 26, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (PAR-25-107). This initiative invites grant applications that explore the use of bacteria, archaebacteria, bacteriophages, and non-oncolytic viruses to investigate their interactions with tumors and the immune system, aiming to develop innovative strategies for cancer imaging and therapy, particularly for oral cancers. The program encourages multidisciplinary collaboration among experts in microbiology, cancer biology, and immunology to address challenges associated with solid tumors and metastases. Applications will be accepted starting January 5, 2025, with no budget limit, and the project period can extend up to five years. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Discovery and Development of Novel Therapeutics for Select Fungal Pathogens (R21/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Discovery and Development of Novel Therapeutics for Select Fungal Pathogens" under the R21/R33 grant mechanism. This initiative aims to support early-stage translational research focused on drug discovery and development against significant fungal pathogens, including specific species of Candida, Aspergillus fumigatus, Coccidioides, and Mucorales, in response to the urgent need for new antifungal treatments due to rising drug resistance. The program will utilize a milestone-driven approach over two phases, with funding limits of up to $275,000 for the R21 phase (up to two years) and $300,000 annually for the R33 phase (up to three additional years), with an estimated total commitment of approximately $2.4 million for 8-10 projects in fiscal year 2026. Interested applicants can find more information and submit inquiries via email at grantsinfo@nih.gov, with the application deadline set for January 28, 2025.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (R01 Clinical Trial Not Allowed), aimed at advancing research on the use of microorganisms for cancer treatment and diagnostics. This initiative invites grant applications that explore the interactions between bacteria, archaebacteria, bacteriophages, and tumors, focusing on their potential to enhance cancer imaging, therapeutics, and diagnostics, particularly for solid tumors. The program encourages multidisciplinary collaborations and aims to address current limitations in cancer therapies, with a significant emphasis on improving treatment outcomes in low-resource settings. Interested applicants can find more information and submit their proposals by May 7, 2025, and should direct inquiries to the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs" (R21 Clinical Trial Not Allowed), aimed at advancing research in the use of microorganisms for cancer treatment and diagnostics. This initiative invites grant applications that explore the interactions between microorganisms, tumors, and the immune system, focusing on their potential to develop innovative strategies for cancer imaging and therapeutics, particularly for solid tumors and oral cancers. The program supports exploratory and developmental research with a maximum budget of $275,000 over two years, encouraging multidisciplinary collaboration to address significant challenges in cancer therapy. Applications are due by May 7, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Microbial-based Cancer Imaging and Therapy - Bugs as Drugs," aimed at exploring innovative strategies for cancer therapy and diagnostics utilizing microorganisms. This R21 grant supports exploratory projects that investigate the interactions between tumors and microorganisms, such as bacteria and viruses, with a focus on enhancing immune responses and developing new imaging technologies, particularly for solid tumors and oral cancers. The initiative seeks to address critical gaps in current cancer treatment modalities and encourages proposals that demonstrate innovative, multi-disciplinary approaches. Eligible applicants can request funding up to $275,000 over a two-year project period, with applications due by May 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-086.html.
    Complement-ARIE New Approach Methodologies (NAMs) Technology Development Centers (UM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for funding under the Notice of Funding Opportunity (NOFO) aimed at establishing Comprehensive New Approach Methodologies (NAMs) Technology Development Centers through its Complement Animal Research In Experimentation (Complement-ARIE) program. The initiative seeks to expedite the development and validation of human-based NAMs to enhance biomedical research models, with a focus on innovative combinatorial approaches that increase biological complexity and promote data sharing in accordance with FAIR principles. This program is significant as it aims to reshape biomedical research paradigms by reducing reliance on animal testing and supporting personalized medicine. Funding is set at approximately $18 million per year, with a maximum budget of $2 million per project over five years, and applications are due by February 28, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Early Stage Investigator HIV/AIDS Research Using Nonhuman Primate (NHP) Models (R21 Clinical Trial Not Allowed)" aimed at supporting Early Stage Investigators (ESIs) in conducting innovative preclinical research on HIV/AIDS using NHP models. This grant initiative seeks to empower researchers who are within ten years of their terminal degree and have at least two years of postdoctoral experience, enabling them to explore new research directions that align with the NIH Strategic Plan for HIV and HIV-Related Research for FY 2021-2025. The funding provides a maximum of $400,000 over a two-year period, with applications due by September 7, 2025. Interested applicants can find more information and submission guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    PHS 2024-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), in collaboration with the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA), has announced the PHS 2024-2 Omnibus Solicitation for Small Business Innovation Research (SBIR) Grant Applications. This funding opportunity invites eligible U.S. small businesses to submit applications for Phase I, Phase II, Fast-Track, and Direct to Phase II projects that align with the research missions of the NIH, CDC, and FDA, with a focus on stimulating technological innovation and commercialization of federal R&D investments. Notably, applications must not include clinical trials, and funding levels are capped at $306,872 for Phase I and up to $2,045,816 for Phase II, with a submission deadline of April 5, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Human Virome Program: Developing novel and innovative tools to interrogate and annotate the human virome (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the Human Virome Program, which aims to develop innovative tools and methods for characterizing the human virome and understanding its impact on health and disease. This initiative seeks to address technological challenges in identifying and analyzing human-associated viruses, inviting applicants to propose projects that enhance the study of the human virome through novel tools and bioinformatics methods. The program is significant for advancing knowledge that could lead to new health-related biomarkers and therapeutic strategies, with NIH planning to commit approximately $2.5 million to fund 4-5 awards, each with a maximum budget of $350,000 per year for up to four years. Applications are due by January 27, 2025, with the earliest project start date anticipated for July 2025; for further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.